BRCA2 and neoplasm: Thus, as the incidence of PIK3CA mutations in tumours from in BRCA2 carriers is likely to be negligible, these patients are unlikely to derive benefits from the PIK3CA inhibitors that are now entering clinical trials for female breast cancer [19].